List of Excipients in Branded Drug RESTASIS MULTIDOSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	RESTASIS MULTIDOSE	cyclosporine	0023-5301	CARBOMER COPOLYMER TYPE A
Allergan Inc	RESTASIS MULTIDOSE	cyclosporine	0023-5301	CASTOR OIL
Allergan Inc	RESTASIS MULTIDOSE	cyclosporine	0023-5301	GLYCERIN
Allergan Inc	RESTASIS MULTIDOSE	cyclosporine	0023-5301	POLYSORBATE 80

Restasis MultiDose Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Restasis MultiDose is a preservative-free cyclosporine ophthalmic emulsion containing 0.05% cyclosporine. Its commercial differentiation depends less on the active ingredient than on emulsion stability, ocular tolerability, multidose delivery, microbial-control engineering, and patient adherence. The largest opportunities are preservative-free generic substitution, higher-concentration cyclosporine products, device-enabled delivery, and excipient systems that improve comfort, shelf life, and dose uniformity.

What is Restasis MultiDose?

Restasis MultiDose is Allergan’s multidose presentation of cyclosporine ophthalmic emulsion, later commercialized within AbbVie’s ophthalmology portfolio. The product is approved to increase tear production in patients whose tear production is suppressed because of ocular inflammation associated with keratoconjunctivitis sicca, commonly called dry-eye disease.[1]

Attribute	Restasis MultiDose
Active ingredient	Cyclosporine
Strength	0.05% ophthalmic emulsion
Dosage form	Topical ophthalmic emulsion
Administration	One drop in each affected eye twice daily
Preservative status	Preservative-free
Therapeutic category	Immunomodulatory dry-eye therapy
Original innovator	Allergan
Current commercial owner	AbbVie
Primary formulation challenge	Maintaining a stable, comfortable, sterile emulsion in a multidose container

The multidose version is designed to replace repeated single-use vials with a bottle-based delivery system. That change creates a distinct product-development problem: the formulation must remain microbiologically suitable during repeated use without relying on conventional preservatives that may worsen ocular-surface irritation.

What excipients are used in Restasis MultiDose?

The FDA prescribing information identifies glycerin, castor oil, polysorbate 80, carbomer copolymer Type A, purified water, and sodium hydroxide among the inactive ingredients.[1]

Excipient	Likely formulation function
Glycerin	Humectant, tonicity modifier, and comfort-supporting excipient
Castor oil	Lipid phase and vehicle for cyclosporine
Polysorbate 80	Surfactant and interfacial stabilizer
Carbomer copolymer Type A	Viscosity modifier and emulsion-supporting polymer
Purified water	Continuous aqueous phase
Sodium hydroxide	pH adjustment

Cyclosporine is highly lipophilic and has limited water solubility. The formulation therefore uses an oil-in-water emulsion rather than a simple aqueous solution. Castor oil provides the lipid environment needed to solubilize or disperse cyclosporine. Polysorbate 80 helps stabilize the oil-water interface and supports dispersion of the lipid droplets through the aqueous phase.

Carbomer increases viscosity and can improve residence time on the ocular surface. Excessive viscosity, however, can cause blurred vision, poor drop formation, or a heavier ocular sensation. Glycerin supports osmotic balance and may reduce the discomfort associated with an ophthalmic emulsion.

The excipient system is commercially important because the product must balance several competing requirements:

1. Cyclosporine solubilization or uniform dispersion.
2. Physical stability over the labeled shelf life.
3. Rapid redispersion after storage.
4. Consistent delivered drop size.
5. Low ocular irritation.
6. Preservative-free multidose use.
7. Sterility through repeated opening and administration.

Why is the preservative-free multidose strategy commercially valuable?

Preservatives such as benzalkonium chloride can damage the ocular surface with repeated exposure, particularly in patients with chronic dry-eye disease. A preservative-free product can therefore support long-term use and physician preference, especially among patients with moderate-to-severe disease or pre-existing ocular-surface disease.

The commercial advantage of a multidose presentation is convenience. Patients do not need to open and discard a separate vial for every administration. A multidose bottle can reduce packaging waste, improve portability, and simplify twice-daily treatment.

The tradeoff is device complexity. A conventional bottle can allow microbial ingress after opening. Restasis MultiDose therefore depends on a dispensing system that limits contamination while maintaining accurate dose delivery. The device is part of the product’s commercial and technical barrier even when the formulation chemistry is publicly disclosed.

What formulation attributes must a competitor reproduce?

A cyclosporine ophthalmic emulsion competitor must generally match more than the nominal 0.05% strength. The relevant performance attributes include:

Emulsion droplet size

Droplet-size distribution affects physical stability, dose uniformity, ocular sensation, and potentially drug availability at the ocular surface. A competitor with a materially different droplet profile may face additional comparative-performance work.

Viscosity and rheology

Viscosity affects retention time, drop formation, blinking sensation, and visual disturbance. Carbomer concentration, neutralization level, and interactions with surfactants can materially change product behavior.

pH and osmolality

The formulation must remain compatible with the ocular surface while preserving cyclosporine stability and emulsion integrity. Changes in pH can affect polymer hydration, interfacial behavior, and comfort.

Redispersibility

A stable emulsion should redisperse consistently after storage and normal handling. Phase separation, creaming, sedimentation, or irreversible aggregation can undermine dose consistency.

Container closure performance

The bottle must control microbial ingress, minimize evaporation, preserve the formulation, and deliver a reproducible drop. Container materials can interact with surfactants, oils, or cyclosporine.

Extractables and leachables

A multidose ophthalmic package requires evaluation of compounds that can migrate from the container, closure, actuator, or protective components into the formulation. Lipid-containing formulations can present particular compatibility concerns.

What commercial opportunities exist around Restasis MultiDose excipients?

Preservative-free generic cyclosporine emulsions

The primary opportunity is an FDA-approved generic or authorized-generic equivalent using a comparable excipient architecture. FDA-approved cyclosporine ophthalmic emulsion products have entered the market, increasing price competition against Restasis.[2]

A generic developer can compete through:

• Lower acquisition cost.
• Retail and specialty-pharmacy distribution.
• Equivalent preservative-free positioning.
• Improved bottle ergonomics.
• Larger package sizes.
• Payer formulary access.
• Lower patient copay.

The core challenge is demonstrating pharmaceutical equivalence and comparable product performance for a complex emulsion rather than a simple aqueous solution.

Higher-concentration cyclosporine products

Sun Pharma’s Cequa, a 0.09% cyclosporine ophthalmic solution, illustrates a separate commercial strategy: increasing cyclosporine concentration and using a different delivery technology.[3] A higher-strength product may support differentiation in efficacy, dosing, or delivery, although it cannot assume automatic substitution for Restasis.

Alternative emulsion systems

Potential excipient strategies include:

• Other ophthalmically acceptable oils.
• Alternative nonionic surfactants.
• Phospholipid-based systems.
• Polymer combinations that improve residence time.
• Reduced-surfactant formulations.
• Nanoemulsions or submicron dispersions.
• In situ gelling systems.

Each approach must demonstrate ocular tolerability and long-term physical stability. A formulation that increases retention but causes blurred vision or stinging may have weak commercial value.

Device-enabled differentiation

The multidose bottle creates opportunities for device suppliers and combination-product developers. Potential improvements include:

• One-way valves.
• Airless dispensing systems.
• Metered-dose pumps.
• Tip designs that reduce contamination.
• Dose counters.
• Ergonomic actuators for patients with arthritis or reduced dexterity.

Device differentiation can support a branded follow-on product even where the active ingredient and broad excipient classes are established.

How strong is the Restasis MultiDose patent estate?

Restasis historically generated substantial patent litigation involving cyclosporine ophthalmic emulsions, formulation claims, methods of treating dry eye, and patent-term issues. The product’s commercial protection was based on a combination of listed patents, formulation know-how, regulatory exclusivity, and device or manufacturing barriers.

The most relevant patent categories are:

Patent category	Commercial relevance
Cyclosporine ophthalmic formulation	Protects composition, emulsion architecture, or excipient relationships
Method of treating dry eye	Can delay or complicate generic launch if listed and enforceable
Multidose delivery system	Protects contamination-control and dose-delivery features
Manufacturing process	Protects homogenization, sterilization, filling, or particle-size control
Container closure	Protects package compatibility and dispensing performance

The practical strength of the estate depends on claim scope, expiration, prosecution history, validity risk, and whether a generic can design around the claims while meeting FDA equivalence requirements. Composition patents generally have greater commercial relevance than narrow process claims because a competitor may avoid a process claim through alternative manufacturing.

Restasis is a small-molecule ophthalmic product, not a biologic. Biosimilar litigation and the Biologics Price Competition and Innovation Act pathway do not apply. Competitive entry occurs through the abbreviated new drug application pathway for generics rather than through biosimilar applications.

What is the Orange Book and Paragraph IV status of Restasis?

Restasis is an FDA-listed drug product, and its patent and exclusivity history is evaluated through the FDA Orange Book and associated FDA records.[4] Generic applicants may submit Paragraph IV certifications alleging that listed patents are invalid, unenforceable, or not infringed.

Restasis-related patent litigation has involved major generic manufacturers, including challenges associated with Allergan’s cyclosporine ophthalmic products. The principal business issue in such cases is whether a generic applicant can launch before all relevant patent barriers expire or whether litigation and settlement delay entry.

A Paragraph IV filing can create:

• A 30-month stay of FDA approval under applicable statutory conditions.
• Patent litigation in federal court.
• Potential first-filer advantages.
• Settlement negotiations involving launch dates, licenses, or authorized-generic arrangements.
• Risk of at-risk launch if the applicant launches before final patent resolution.

The live Orange Book listing, patent expiration dates, and litigation status must be assessed from current FDA and court records because listed patents and litigation positions can change over time.

When does Restasis lose exclusivity?

Restasis has already faced generic competition in the U.S. market. The loss of practical exclusivity has resulted from patent expiry, patent litigation outcomes, settlements, and approval of competing cyclosporine products rather than from a single event.

Commercial exclusivity should be separated into four categories:

Exclusivity type	Relevance to Restasis
New chemical entity exclusivity	Historical FDA exclusivity associated with the original active ingredient
Pediatric exclusivity	Applies only if granted for qualifying studies
Patent exclusivity	Depends on enforceable formulation, method, or device claims
Market exclusivity	Depends on FDA approval and product-specific regulatory history

For investors and licensing teams, the important question is no longer whether generic entry is possible. It is how much share remains defensible through brand loyalty, formulary position, device convenience, supply reliability, and differentiated patient experience.

Which companies compete with Restasis?

The principal competitive set includes generic cyclosporine products, Cequa, Xiidra, and other prescription dry-eye therapies.

Product	Active ingredient	Key differentiation
Restasis MultiDose	Cyclosporine 0.05%	Established brand, preservative-free multidose delivery
Restasis single-use vial	Cyclosporine 0.05%	Preservative-free unit-dose presentation
Cequa	Cyclosporine 0.09%	Higher concentration and nanomicellar delivery technology
Xiidra	Lifitegrast	Different mechanism and formulation
Generic cyclosporine emulsions	Cyclosporine	Price competition and payer substitution

Restasis retains commercial value through physician familiarity, extensive market history, and patient recognition. Generic products place pressure on net pricing and payer access. Cequa competes through formulation and concentration rather than direct duplication.

What manufacturing barriers protect the product?

The principal manufacturing barriers are process-control requirements rather than raw-material scarcity. Critical operations include:

• Preparation of the oil phase.
• Cyclosporine incorporation.
• Emulsification and homogenization.
• Control of droplet-size distribution.
• Polymer hydration and viscosity control.
• Sterile processing or aseptic filling.
• Bottle and closure assembly.
• Container-closure integrity testing.
• Stability testing under long-term and accelerated conditions.

A developer may reproduce the listed inactive ingredients and still fail to achieve comparable performance because manufacturing conditions determine interfacial structure, droplet size, viscosity, and redispersibility.

Contract manufacturers with sterile ophthalmic filling capacity, validated emulsion equipment, and compatible multidose packaging have a commercial advantage. Licensing opportunities are strongest where a supplier combines formulation know-how with a qualified ophthalmic manufacturing platform.

What is the revenue exposure from generic competition?

Restasis has historically been a major ophthalmology product, but revenue exposure has shifted from pure product exclusivity to portfolio economics. Generic substitution can reduce brand volume and price, while the broader dry-eye market continues to support demand for prescription immunomodulatory therapy.

Revenue sensitivity is highest in:

• Commercial plans with mandatory generic substitution.
• Medicare Part D formularies.
• High-volume retail channels.
• Patients without brand loyalty.
• Markets where multiple cyclosporine products receive preferred status.

Revenue durability is stronger in:

• Specialty ophthalmology practices.
• Patients stabilized on a familiar product.
• Plans that preserve brand access.
• Markets where device tolerability affects persistence.
• Patients who experience poor comfort or adherence with alternatives.

The most defensible commercial asset is therefore a combination of formulation, device, supply reliability, and payer positioning rather than the cyclosporine molecule alone.

Key Takeaways

• Restasis MultiDose uses a preservative-free cyclosporine oil-in-water emulsion.
• The disclosed excipient system includes glycerin, castor oil, polysorbate 80, carbomer copolymer Type A, purified water, and sodium hydroxide.
• The main technical barrier is integrating emulsion stability with preservative-free multidose dispensing.
• Generic opportunities center on pharmaceutical equivalence, device performance, manufacturing consistency, and lower cost.
• Cequa competes through a higher cyclosporine concentration and nanomicellar delivery system.
• Restasis is a small-molecule drug, so biosimilar risk does not apply.
• Patent value is concentrated in formulation, method-of-use, delivery-device, container, and manufacturing claims.
• Commercial defense increasingly depends on patient comfort, adherence, payer position, and device convenience.

FAQs

Can a generic Restasis product use different excipients?

Yes. A generic may use different inactive ingredients if it satisfies applicable FDA requirements for pharmaceutical equivalence, safety, performance, and product quality. For a complex ophthalmic emulsion, differences in excipients may require substantial comparative characterization.

Is Restasis MultiDose preservative-free?

Yes. The product is labeled as a preservative-free cyclosporine ophthalmic emulsion. Its multidose presentation depends on the container and dispensing system rather than conventional antimicrobial preservatives.

Does Restasis MultiDose have a formulation patent?

Restasis has been associated with formulation, method-of-use, delivery, and manufacturing patent protection. The enforceability and expiration of any specific patent depend on the patent record and current litigation status.

Is Cequa interchangeable with Restasis?

No. Cequa and Restasis contain cyclosporine but differ in concentration and delivery technology. They are competing prescription products, not automatically interchangeable products.

What is the strongest licensing opportunity around Restasis-type products?

The strongest opportunities are preservative-free multidose delivery systems, stable cyclosporine emulsions with improved comfort, sterile ophthalmic manufacturing platforms, and packaging technologies that improve contamination control and dose consistency.

References

1. U.S. Food and Drug Administration. (2024). Restasis (cyclosporine ophthalmic emulsion) 0.05% prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Sun Pharmaceutical Industries Ltd. (2024). Cequa (cyclosporine ophthalmic solution) 0.09% prescribing information.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.